drugset / Trial / NCT04717999
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot phase I study to evaluate the safety and efficacy of NKG2D CAR-T cell therapy in patients with relapsed and/or refractory glioblastoma
Timeline
- Start
- 2021-09-01
- Primary completion
- 2023-09-30
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NKG2D CAR-T | Cell therapy | — | Other |